Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center
Journal of B.U.ON., cilt.26, sa.5, ss.2026-2032, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 26 Sayı: 5
- Basım Tarihi: 2021
- Dergi Adı: Journal of B.U.ON.
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Sayfa Sayıları: ss.2026-2032
- Anahtar Kelimeler: Acute myeloid leukemia, Relapsed/refractory, Salvage chemotherapy, Venetoclax
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Purpose: Venetoclax (VEN) is an oral selective inhibitor of antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL-2). Methods: We report 7 relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with venetoclax and hypomethylating agents (HMA). Results: More than half of the patients could go on with venetoclax for only a few months. Conclusion: Using venetoclax combined with HMA in R/R AML should be kept in mind as an alternative salvage option.